The Study of Cytokine-induced Killer Cells Treating Patients with Advanced Non-small Cell Lung Cancer after Chemotherapy
-
摘要:
目的探观察化疗后晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者给予细胞因子诱导的杀伤细胞（cytokine-induced killer cells, CIK）治疗后免疫功能及生活质量变化，探讨CIK细胞治疗晚期肺癌的近期疗效及安全性。 方法收集化疗后晚期NSCLC患者61例，选取同期最佳支持治疗的61例化疗后晚期NSCLC患者作为对照组，比较CIK细胞治疗后外周血T淋巴细胞亚群、KPS评分、近期疗效及评估安全性。 结果CIK治疗组患者外周血CD3+、CD3+/CD4+细胞比率较治疗前显著上升（P < 0.05），对照组T淋巴细胞亚群没有变化。CIK细胞治疗后患者KPS评分为67.27±8.94，较治疗前显著提高（P < 0.05）。CIK治疗组疾病控制率为85.25%，显著高于对照组的59.01%（P < 0.05）。CIK治疗组中出现4例一过性发热和3例皮疹患者，未见其他明显毒副作用。 结论CIK治疗化疗后晚期非小细胞肺癌患者，改善免疫功能及生活质量，提高近期疾病控制率，安全性好。 -
关键词:
- 胞因子诱导的杀伤细胞 /
- 非小细胞肺癌 /
- 免疫系统 /
- 生活质量 /
- 疗效
Abstract:ObjectiveTo investigate the changes of immunity and life quality after the treatment of cytokine induced-killer cells (CIKs) for patients with advanced NSCLC after chemotherapy, and to assess the effectiveness and safety of CIKs treatment. MethodSixty-one patients with advanced NSCLC after chemotherapy treated with CIKs were enrolled as CIKs group, and another sixty-one post-chemotherapy patients of advanced NSCLC treated with optimal supportive care during the same period were enrolled as control group. Before and after CIK cells being transfused back, the changes of immune system including subsets of T cells, quality of life (Karnofsky score), therapeutic effects and side effects were compared between the two groups. ResultCompared with before CIK cells therapy, the ratios of CD3+and CD3+/CD4+T cells significantly increased (P < 0.05), while there was no significant change in the control group. KPS score significantly increased in the CIKs group, which was 67.27±8.94(P < 0.05). The disease control rate (DCR) were 85.25% in the CIKs group, which was significantly higher than those in the control group (59.01%)(P < 0.05). The major adverse events were transient fever and skin rash, and no other side effect was observed. ConclusionCIK cells treatment is safe and effective for advanced NSCLC patients. It can improve the immune imbalance, DCR and quality of life of the patients. -
Key words:
- cytokine-induced killer cell /
- NSCLC /
- immunity /
- effectiveness /
- quality of life
-
表 1 61例患者治疗前后外周血T细胞表型变化
Table 1. Changes of T-cell phenotype in peripheral blood of 61 patients after CIK cells treatment (%, x±s, n=61)
组别 CIK组 对照组 CD3（%） CD3+/CD4+（%） CD3+/CD8+（%） CD3（%） CD3+/CD4+（%） CD3+/CD8+（%） 治疗前 65.32±9.41 39.78±8.29 25.13±9.26 66.15±10.52 40.43±9.36 24.87±10.28 治疗后 70.70±8.97* 45.26±10.34* 27.88±9.57 65.39±10.22 39.67±8.25 24.18±8.97 与治疗前比较，*p < 0.05. 
下载: 导出CSV
表 2 CIK细胞治疗前后Karnofsky评分
Table 2. The Karnofsky score of 61 patients before and after CIK cells treatment (x±s, n=61)
组别 治疗前 治疗后 对照组 60.41±8.55 61.34±7.65 CIK组 60.87±6.93 67.27±8.94* 与治疗前比较，*P<05.
下载: 导出CSV
表 3 近期疗效评价
Table 3. Short term evaluation of therapeutic effects (x±s, n=61)
组别 CR PR SD PD ORR (%) DCR (%) 对照组 2 15 19 25 27.87 59.01 CIK组 3 16 33 9 31.15 85.25* 与治疗前比较，*P < 0.05.
下载: 导出CSV
-
[1] Jemal A, Bray F, Center MM, et al. Global Cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. doi: 10.3322/caac.v61:2 [2] Szkorupa M, Klein J, Bohanes T, et al. Neoadjuvant chemotherapy and surgical treatment in advanced stages of non-small cell lung cancer[J]. Rozhl Chir, 2011, 90(8): 433-9. https://www.ncbi.nlm.nih.gov/pubmed/22272471 [3] Baas P, Belderbos JS, van den heuvel M.Chemoradiation therapy in non-small cell lung cancer[J]. Curr Opin Oncol, 2011, 23(2): 140-9. doi: 10.1097/CCO.0b013e328341eed6 [4] 张俊萍, 毛光华, 史天良, 等. DC-CIK联合化疗治疗晚期非小细胞肺癌的临床疗效[J].中国肿瘤生物治疗杂志, 2011, 18(4): 424-9. http://mall.cnki.net/magazine/Article/ZLSW201104021.htm [5] Stroncek D, Berlyne D, Fox B, et al. Developments in clinical cell therapy[J]. Cytotherapy, 2010, 12(3): 425-8. doi: 10.3109/14653240903511952 [6] Helms MW, Prescher JA, Cao YA, et al. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immu notherapy[J]. Cancer Immunol Immunother, 2010, 59(9): 1325-34. doi: 10.1007/s00262-010-0860-y [7] Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery[J]. Cytotherapy, 2009, 11(8): 1076-83. doi: 10.3109/14653240903121252 [8] 杨志银, 王燕. CIK维持治疗中晚期肺癌的临床观察及影响因素分析[J].临床肺科杂志, 2014, 19(4): 706-9. http://www.cnki.com.cn/Article/CJFDTOTAL-WSCY201334084.htm [9] 罗虎, 宫亮, 陈永峰, 等. CIK维持治疗中晚期肺癌的临床观察及影响因素分析[J].第三军医大学学报, 2013435(6): 569-72. http://www.cnki.com.cn/Article/CJFDTOTAL-DSDX201306024.htm -
点击查看大图
表(3)
计量
- 文章访问数: 630
- HTML全文浏览量: 180
- PDF下载量: 6
- 被引次数: 0
